Evidence map›Paper›PMID 41384820›Full record

ReviewThe American journal of gastroenterology2026

Budd-Chiari Syndrome: Presentation, Management, and Prognosis.

Waseem Amjad, Paul J Thuluvath

Abstract readReview
In one paragraph

Review in The American journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Waseem AmjadInstitute of Digestive Health & Liver Disease, Mercy Medical Center, Baltimore, Maryland, USA.ORCID 0000-0002-9718-1076
Paul J ThuluvathInstitute of Digestive Health & Liver Disease, Mercy Medical Center, Baltimore, Maryland, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Budd-Chiari syndrome (BCS) is a rare condition characterized by hepatic vein obstruction causing liver congestion, dysfunction, and rarely liver failure. BCS may present as acute, subacute, or chronic liver disease. It usually presents at a younger age as compared with other splanchnic thrombotic conditions. Prothrombotic conditions, myeloproliferative disorders, and oral contraceptives use are common risk factors. In addition, lower socioeconomic status and malnutrition are associated with BCS. Many prognostic scores are available, and they are useful for general guidance. A stepwise treatment strategy is recommended for the management of BCS, starting with anticoagulation followed by portosystemic shunting and liver transplantation for most patients with BCS, but such a strategy may not be applicable in those who present with acute liver failure. Post liver transplant survival outcomes in BCS, including in those who present with acute liver failure and multiple organ failures, are comparable with other indications. Pregnancy is not contraindicated in those with BCS, and maternal outcomes are favorable, but fetal outcomes remain poor. Most patients with BCS, including those who had liver transplantation, require lifelong anticoagulation. There are limited data on chronic BCS, and these patients are often diagnosed with complications of portal hypertension or liver cancer. In this review, we discuss our current understanding of etiologies, diagnostic options and prognostic scores, natural history including pregnancy outcomes, and treatment outcomes of BCS.

Indexed as

Budd-Chiari SyndromeAnticoagulantsFemaleHumansLiver TransplantationPregnancyPrognosisRisk FactorsAnticoagulantsBudd-Chiari syndromehepatitic venous thrombosisliver transplantationprognosis

Identifiers

PMID41384820
PMCPMC13313475

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.